platoseedplatoseed
We use AI to design antibodies for intractable diseases
Our mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, we design antibodies that precisely bind the disease target at the right location, while minimizing manufacturability and toxicity risks. We are a well-funded, revenue-generating, bilingual company of wet- and dry-lab scientists, and are founded by AI and protein design experts from Harvard University.
Nabla Bio designs antibodies using AI to create drug-like antibodies from computer design, aiming to reduce trial-and-error in drug development. They combine de novo design with human-relevant testing and own data, AI, and wet/dry lab integration as an engine to design medicines with desired properties.
A platform that pairs generative drug design with large-scale, human-relevant testing to design antibodies and medicines in silico and validate them through integrated dry/wet-lab workflows. The approach involves owning the data, AI models, and laboratory systems to produce molecules with specific binding, developability, cellular function, and in-vivo performance, enabling faster, safer, and more precise drug design.
Who it’s for: Pharmaceutical companies and biotech organizations seeking to design antibodies and novel medicines with AI-driven planning and integrated testing
Hiring; mentions of careers and partnerships; Cambridge, MA location; public announcements (Technical Reports, News)
Currently building Nabla Bio. I'm a scientist with 10+ years of experience with using synthetic biology and machine learning to engineer everything from the microbiome to proteins. I recently completed my PhD from George Church's lab at Harvard.
Currently building Nabla Bio! I've spent the last 8 years applying my chemistry training to problems in biology and specifically synthetic biology. I did my PhD at Harvard (Class 2019, BBS) and spent some time in biotech VC.
Formerly “Inc” · why startups rename →
We create activating antibodies to treat diseases others can’t.
AI-designed Affinity Reagents
